Inflammation Markers Before, During and After a GLP-1 or Peptide: What hs-CRP Can Show

The short version

• hs-CRP is a simple blood test for inflammation. It shows that your immune system is busy somewhere. It does not say where or why.
• A "before" reading is your reference point. Take it when you are well, with no recent cold, injury or very hard training, and use the same lab each time.
• GLP-1 medicines lower hs-CRP in large trials. Semaglutide and tirzepatide both did, and the fall mostly goes along with weight loss.
• For peptides sold as "anti-inflammatory", like BPC-157 and KPV, there are no human hs-CRP studies in well people. That is unestablished, not disproven: the trials have not been run or funded. So a change in your number cannot be credited to the peptide.
• Used well, hs-CRP is a useful check-in. A fair baseline, a few planned repeats and your other bloodwork together tell you far more than any single number.

Educational content, not medical advice. No doses or protocols appear.

---

hs-CRP in one paragraph

C-reactive protein (CRP) is a protein your liver makes when your immune system is switched on. That can be by an infection, an injury, a long-term condition or extra body fat. "High-sensitivity" (the "hs") just means the lab uses a method that can measure small amounts. It is the same protein as ordinary CRP. The test is non-specific: it tells you something is stirring, not what or where. For the full background, including why a marker is not a target, read our main guide on what hs-CRP measures. This page is the practical companion: how to use the test around a GLP-1 medicine or a peptide.

Why take a "before" reading

A number only means something when you can compare it with another number. If you start a new medicine and test hs-CRP three months later, you need to know where you started. Otherwise a result has nothing to be measured against.

People differ, so your own starting point matters more than a population average.

How to get a fair reading

hs-CRP reacts quickly to everyday events. To get a reading that reflects your usual state, aim for these conditions:

• You are well. No cold, flu, stomach bug or fever recently. CRP can stay raised for a while after you feel better.
• No recent injury, surgery or dental work. Even a tooth extraction can push it up.
• No unusually hard training in the days before. A tough session that is new to your body can raise it for a short time.
• Same lab, each time. Different labs can use different equipment. Switching makes small changes hard to read.
• Similar conditions each time. Similar time of day, similar routine, and tell whoever reads your results about any medicines that contain oestrogen, which can raise CRP.

If one of these is off, it is usually better to wait and test later than to test now and guess.

What is known: GLP-1 medicines

A GLP-1 medicine copies a gut hormone that tells your brain you are full and helps control blood sugar. Semaglutide and tirzepatide are FDA-approved for type 2 diabetes and chronic weight management, plus some specific uses. Tirzepatide also acts on a second gut hormone (GIP).

Here, the evidence on hs-CRP is real and fairly consistent:

• Semaglutide, STEP trials. In three large trials in people with overweight or obesity, CRP fell by roughly 40 to 50 percent more than in people on a dummy treatment. The fall lined up most closely with weight loss. These were extra analyses, done after the main trials.
• Semaglutide, SELECT trial. In about 17,600 adults with heart disease and overweight but no diabetes, hs-CRP was lower than with dummy treatment by about a third at two years. It started falling within the first weeks, before much weight had been lost, and also fell in some people who lost very little weight.
• Tirzepatide, SURMOUNT-1. In a later analysis of this large trial in people with obesity, hs-CRP fell more than with dummy treatment at every dose level. The size of the fall was moderately linked to how much weight and waist people lost.

What does this add up to? The fall is real, and most of it seems to go along with losing body fat, especially belly fat, which sends out signals that drive CRP. A separate direct anti-inflammatory effect is possible but not proven, as the SELECT authors themselves say.

Keep it in proportion. These are group averages: your own number may fall a lot, a little or not at all. And a lower hs-CRP is a sign of what is happening, not a goal in its own right. Lowering CRP for its own sake has not been shown to help, as our main hs-CRP guide explains.

What is not known: peptides marketed as anti-inflammatory

Several peptides are sold online with "anti-inflammatory" claims. The common ones are BPC-157, KPV, thymosin alpha-1 and TB-500. All four are investigational and not FDA-approved in the US.

Here is the honest state of the evidence:

• BPC-157, KPV and TB-500. The "anti-inflammatory" idea comes from lab and animal studies. There are no published human studies measuring what they do to hs-CRP.
• Thymosin alpha-1. It has been studied in some groups of people who were seriously ill, for example small trials in hospital patients with severe pancreatitis, where CRP was one of many things measured. Those results come from very sick people, not healthy adults, and cannot tell you what it does to hs-CRP in someone who is well.

So for all four, the question "does this lower hs-CRP in a person like me?" is unanswered. It is not disproven. The studies simply have not been run or funded.

That has a practical meaning. If your hs-CRP falls while you use one of these peptides, you cannot credit the peptide. Getting over a cold, losing weight, sleeping better, a lighter training week or normal day-to-day swing are all at least as likely. The same is true if the number rises.

How to read a change

A fall during weight loss is expected

If you are losing weight on a GLP-1 medicine, a lower hs-CRP is what the trials would lead you to expect. It is not proof that any peptide you added did anything. Weight loss alone could explain it.

A rise is most often a passing infection

The most common reason for a jump is something ordinary: a cold, a sore throat, a stomach bug, a dental problem or a hard workout. If you were unwell around the test, the usual step is to wait until you are fully better and test again.

Some rises need medical attention

GLP-1 medicines have a few uncommon but known side effects that raise inflammation markers:

• Gallbladder problems, such as gallstones or an inflamed gallbladder. Fast weight loss raises this risk. Read more in GLP-1s and gallbladder risk.
• Pancreatitis, which is inflammation of the pancreas.

Warning signs include strong or lasting pain in the upper belly (sometimes spreading to the back), pain after fatty meals, repeated vomiting, fever, or yellowing of the skin or eyes. If you have these, do not wait for a blood test. Talk to your own doctor or seek urgent care. Our guide on when to call your doctor on a GLP-1 lists more.

One number is not a trend

hs-CRP swings from day to day even in healthy people. A single high or low result is one snapshot. A change usually needs a repeat test, under the same fair conditions, before it means much.

What to test alongside hs-CRP

hs-CRP on its own is a blunt tool. It makes more sense next to a few other markers. We deliberately give no ranges or targets: your lab report shows its own range, and what is normal for you depends on your history.

For a ready-made starting point, see our baseline biomarker panel. For more on why each marker is chosen, see peptide therapy biomarkers and peptide therapy monitoring panels.

A simple before, during and after plan

This is a way to think about timing, not a testing schedule. Agree the actual timing with whoever reviews your results.

Common mistakes

Testing too often. hs-CRP swings naturally. Weekly testing mostly measures noise, and noise causes worry.

Testing when sick. A reading taken during or just after a cold reflects the cold. It tells you nothing about your treatment.

Switching labs. Different labs can give slightly different numbers for the same blood. Stick with one where you can.

Chasing a number. A lower hs-CRP is not a score to beat. Adding products to push it down misses the point: the marker reflects what is happening in your body, it does not cause it. Look for the cause of a change instead.

Frequently asked questions

Does semaglutide or tirzepatide lower hs-CRP? In large trials, yes, on average. Both lowered hs-CRP compared with a dummy treatment, and most of the fall went along with weight loss. Your own result may differ from the average.

Will BPC-157 or KPV lower my hs-CRP? Nobody knows. There are no human studies measuring it. That is unestablished, not disproven, because the trials have not been run or funded. If your number changes while you use one, other explanations are at least as likely.

My hs-CRP went up after I started. Should I worry? Most rises come from a passing infection or a hard workout. Retest when you are well. If you also have belly pain, vomiting, fever or yellowing skin, talk to your own doctor straight away, because gallbladder and pancreas problems are uncommon but known GLP-1 side effects.

What is a good hs-CRP number to aim for? We do not publish targets. What a number means depends on your lab, your health history and the conditions on the day. Your lab report shows its own range, and your trend over time matters more than one value.

Where Vivre Labs fits

Vivre Labs offers access to GLP-1 medicines including semaglutide and tirzepatide, both FDA-approved for type 2 diabetes and chronic weight management. Retatrutide is investigational and not approved anywhere; it is still in late-stage trials.

We also offer investigational peptides. BPC-157 and KPV are supported mainly by animal and lab studies. Thymosin alpha-1 has some human data in specific illnesses and is not FDA-approved in the US. Our calm inflammation and gut protocol brings KPV, VIP and thymosin together; it is also investigational.

Whatever you consider, bloodwork comes first. Our baseline biomarker panel gives you a fair "before" picture, including hs-CRP, so later results have something to be compared with. For the wider picture of what is worth tracking, see peptide therapy biomarkers.

Related reading

• What hs-CRP actually measures (and what it doesn't)
• GLP-1s and gallbladder risk
• Peptide therapy biomarkers
• "Optimal" versus normal lab ranges
• Inflammaging: chronic low-grade inflammation and ageing

Part of The Complete Guide to Inflammation

---

This article is educational and does not constitute medical advice. It deliberately contains no doses, reference ranges, thresholds or target values. Lab results should be read by a qualified healthcare professional who knows your history and medicines. Statements reflect the published evidence at the time of writing. Claims for the Malaysian market are subject to MAB requirements.

References

• Pearson TA, Mensah GA, Alexander RW, et al. "Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice." Circulation, 2003. (Measure hs-CRP in a metabolically stable person without obvious infection; repeat on separate occasions.)
• Verma S, Bhatta M, Davies M, et al. "Effects of once-weekly semaglutide [title dose omitted] on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials." eClinicalMedicine, 2023. CRP versus placebo at week 68: STEP 1 -44%, STEP 2 -39%, STEP 3 -48%; changes correlated most strongly with body weight change. https://pmc.ncbi.nlm.nih.gov/articles/PMC9713290
• Plutzky J, et al. Prespecified secondary analysis of hs-CRP in the SELECT trial (semaglutide in adults with cardiovascular disease and overweight or obesity, without diabetes). Circulation, 2026. Placebo-corrected hs-CRP reduction 37.8% at week 104; reductions seen at weeks 4 and 8 and in participants with minimal weight loss; authors note this does not establish a weight-independent anti-inflammatory mechanism. Summary: https://www.news-medical.net/news/20260824/Semaglutidee28099s-heart-benefits-may-partly-involve-reduced-inflammation.aspx
• Sattar N, Linetzky B, Ruotolo G, Verma S, et al., Ridker PM. "Comprehensive long-term changes in cardiovascular risk biomarkers with tirzepatide: A SURMOUNT-1 post hoc analysis." Journal of the American College of Cardiology, 2026; 88(6): 652-666. hs-CRP fell versus placebo at all dose levels at week 72; change correlated with weight change (r = 0.45) and waist change (r = 0.40); authors state correlations do not allow causal conclusions. https://eprints.gla.ac.uk/388930/
• Systematic review and meta-analysis of thymosin alpha 1 in severe acute pancreatitis (five randomised trials, 706 hospital patients). Frontiers in Immunology, 2025. CRP lower with thymosin alpha 1, with high heterogeneity; authors call for more high-quality research. https://www.frontiersin.org/article/1571456
• Lee E, Padgett B. "Intra-articular injection of BPC 157 for multiple types of knee pain." Alternative Therapies in Health and Medicine, 2021. Uncontrolled retrospective chart review; subjective outcomes only; no control group. (Context for how limited human BPC-157 data are.)